Literature DB >> 9181384

Efficacy of twice-daily dosing of amoxycillin/clavulanate in acute otitis media in children.

U Behre1, H M Burow, P Quinn, F Cree, H E Harrison.   

Abstract

Children with acute otitis media (AOM), aged 2-12 years, were randomised to 10 days treatment with amoxycillin/clavulanate (A/C) 70/10 mg/kg/day given b.i.d. (231 patients) or to A/C 60/15 mg/kg/day given t.i.d. (232 patients). Clinical success rates at end of therapy (10-17 days) were 91.8% for the b.i.d. group and 90.5% for the t.i.d. group and at follow-up (28-42 days) were 80.1% for the b.i.d. group and 77.6% for the t.i.d. group, indicating that the b.i.d. regimen was as effective as the t.i.d. regimen. There was no statistically significant difference in incidence of adverse experiences between the two groups. The overall incidence of protocol defined diarrhoea assessed from diary booklets was low, with a lower incidence in the b.i.d. group (6.7%) than in the t.i.d. group (10.3%). Significantly more patients in the b.i.d. group (83.1%) than in the t.i.d. group (72.8%) had at least 80% compliance over a 7-10 day treatment period. A/C given twice or three-times daily was highly effective in the treatment of AOM in children. The two regimens showed equivalent clinical efficacy, both were well tolerated, and there was evidence of improved compliance with the b.i.d. regimen.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181384     DOI: 10.1007/BF02113605

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  8 in total

1.  Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children.

Authors:  J M McCarty; A Phillips; R Wiisanen
Journal:  Pediatr Infect Dis J       Date:  1993-12       Impact factor: 2.129

2.  A randomized controlled trial of amoxicillin plus clavulanate compared with cefaclor for treatment of acute otitis media.

Authors:  C D Marchant; P A Shurin; C E Johnson; D Murdell-Panek; J C Feinstein; D Fulton; P Flexon; S A Carlin; G F Van Hare
Journal:  J Pediatr       Date:  1986-11       Impact factor: 4.406

3.  Comparison of cefuroxime axetil and amoxicillin-clavulanate suspensions in treatment of acute otitis media with effusion in children.

Authors:  S E McLinn; M Moskal; J Goldfarb; F Bodor; G Aronovitz; R Schwartz; P Self; M J Ossi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

4.  Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children.

Authors:  U B Schaad
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

5.  Ascertaining how much compliance is enough with outpatient antibiotic regimens.

Authors:  J Urquhart
Journal:  Postgrad Med J       Date:  1992       Impact factor: 2.401

6.  Ten-year review of otitis media pathogens.

Authors:  C D Bluestone; J S Stephenson; L M Martin
Journal:  Pediatr Infect Dis J       Date:  1992-08       Impact factor: 2.129

Review 7.  Antibiotic prescribing practices and patient compliance in the community.

Authors:  P R Grob
Journal:  Scand J Infect Dis Suppl       Date:  1992

8.  Epidemiology of otitis media in children.

Authors:  D W Teele; J O Klein; B A Rosner
Journal:  Ann Otol Rhinol Laryngol Suppl       Date:  1980 May-Jun
  8 in total
  3 in total

Review 1.  Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials.

Authors:  Jemima Kuehn; Zareen Ismael; Paul F Long; Charlotte I S Barker; Mike Sharland
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Mar-Apr

Review 2.  Amoxicillin/clavulanic acid: a review of its use in the management of paediatric patients with acute otitis media.

Authors:  Jane Easton; Stuart Noble; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

3.  Compliance with once-daily versus twice or thrice-daily administration of antibiotic regimens: a meta-analysis of randomized controlled trials.

Authors:  Matthew E Falagas; Apostolos K A Karagiannis; Theodora Nakouti; Giannoula S Tansarli
Journal:  PLoS One       Date:  2015-01-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.